{
  "abstract": "Background/Aim: KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) has a transcriptional program, but its relationship to drug sensitivity remains incompletely characterized. This study investigated whether a KMT2A-r-like transcriptomic state is associated with ex vivo kinase inhibitor sensitivity.\n\nMaterials and Methods: TARGET-AML RNA-sequencing data with fusion and cytogenetic annotations were used to define a predefined, biology-informed, continuous KMT2A-r identity score based on KMT2A-rearrangement-associated genes. The score was applied to Beat AML primary samples with matched normalized expression, ex vivo drug-response area under the curve (AUC) values, malignant cell-type scores, and FLT3-internal tandem duplication status. Associations were assessed using Spearman correlation and covariate-adjusted linear regression.\n\nResults: KMT2A-r AML exhibited increased expression of HOXA genes, MEIS1, PBX3, MEF2C, and FLT3 in TARGET-AML. The identity score differentiated KMT2A-r AML from other fusion groups in TARGET-AML; when applied to Beat AML, higher KMT2A-r identity scores were associated with lower AUC values for kinase inhibitors. After adjustment for malignant cell-type scores and FLT3-internal tandem duplication status, cabozantinib, sorafenib, and pelitinib retained significant negative associations with AUC. Further adjustment for FLT3 expression attenuated these associations, whereas an FLT3-excluded score preserved their direction.\n\nConclusion: A KMT2A-r-like transcriptomic state is associated with candidate kinase inhibitor sensitivity patterns in primary AML datasets and appears linked to, but not fully explained by, FLT3-related biology.",
  "abstract_shown": true,
  "affiliations": [
    "School of Life Science and Biotechnology, BK21 Plus KNU Creative BioResearch Group, Kyungpook National University, Daegu, Republic of Korea"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "WONWOO CHOI"
    },
    {
      "affs": [
        0
      ],
      "name": "SANGGYU LEE"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6d11231q5ejnf.bib",
  "cited_by": 0,
  "doi": "10.21873/cgp.20621",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13724014/",
  "id": "6d11231q5ejnf",
  "issns": [
    "1109-6535",
    "1790-6245"
  ],
  "landing_url": "https://doi.org/10.21873/cgp.20621",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2720|Acute Myeloid Leukemia Research"
    ]
  ],
  "openalex": "W7224993218",
  "pdf_url": null,
  "pmcid": "PMC13724014",
  "pmid": "42966630",
  "published": "2026-10-31",
  "publisher": "International Institute of Anticancer Research",
  "ris": "https://research.draconitic.com/paper/6d11231q5ejnf.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:22:33Z",
      "native_id": "PMC13724014",
      "source": "pmc",
      "url": "https://doi.org/10.21873/cgp.20621"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2720|Acute Myeloid Leukemia Research",
      "subfield": "general"
    }
  ],
  "title": "Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A- Rearranged AML",
  "title_text": "Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A- Rearranged AML",
  "type": "peer-reviewed",
  "updated_at": "2026-11-05T12:20:44Z",
  "url": "https://research.draconitic.com/paper/6d11231q5ejnf",
  "venue": "Cancer Genomics & Proteomics",
  "versions": []
}